Recovering scientist turned early stage VC A biotech optimist fighting gravity

The Biotech Juggling Act: Keeping all the Balls in the Air
March 20, 2025

“When the going gets tough, the tough get going” By Ram Aiyar, CEO of Korro Bio, as part of the From the Trenches feature of LifeSciVC. It has been quite a start to the 2025 year. The sentiment around biotech

Leave a comment

 The Sweetest Thing
March 12, 2025

By Arthur Tzianabos, CEO of Lifordi Immunotherapeutics, as part of the From The Trenches feature of LifeSciVC Given everything going on in our world right now, I’ve been thinking a lot about the state of biotech innovation…particularly as we wrestle

Leave a comment

Pitfalls Of The Scarcity Mindset
February 28, 2025

By Ankit Mahadevia, serial biotech entrepreneur and former CEO of Spero Therapeutics, as part of the From The Trenches feature of LifeSciVC I recently had an illuminating discussion with a seed-stage biotech Founder, who was reflecting after a hard and

Leave a comment

Dancing with the DGC: Structural Biology Meets Muscular Dystrophy
February 18, 2025

By Cody Tranbarger, EIR at Atlas Venture, as part of the From The Trenches feature of LifeSciVC For decades, muscular dystrophy has stubbornly persisted among the most intractable categories of human disease. Despite recent progress with AAV Gene Therapy and

Leave a comment

A New Wave of Therapeutic Innovation Through Targeting Transcription Factors
February 5, 2025

By Jonathan Montagu, CEO of HotSpot Therapeutics, as part of the From The Trenches feature of LifeSciVC In the perpetual and never-ending race by the healthcare sector to unearth new approaches and therapeutics to address disease, one area in which

Leave a comment

A Tale of Two Sentiments: JPM 2025
January 21, 2025

By Aimee Raleigh, Principal at Atlas Venture, as part of the From The Trenches feature of LifeSciVC “It was the best of times, it was the worst of times…” Another JPM is behind us, and while much of the small

Leave a comment

Atlas XIV And Reflections On The VC Math Problem
December 5, 2024

Today we announced the closing of Atlas Venture Fund XIV, a $450M investment vehicle focused exclusively on early stage biotech investing. With the closing of Fund XIV, we’re privileged to be able to continue backing innovative new biotech companies for

Leave a comment

Atlas Venture 2024 Year In Review
November 18, 2024

“May you live in interesting times” – or so goes the phrase. In 1966, RFK Jr’s father famously used that quote to capture the turbulence of the times, and continued: “Like it or not, we live in interesting times. They

Leave a comment

Biotech Risk Cycles: Assets And Platforms
October 28, 2024

Today’s market likes products. Platforms aren’t in vogue anymore. Investors, especially in the public markets, only want late stage de-risked assets. Pharma only seems to be buying these kinds of asset. VCs need to focus on clinical stage companies. Or

Leave a comment

ESMO Reflections: Glimmers of Hope with the Next Wave of I-O Therapies?
October 10, 2024

By Jonathan Montagu, CEO of HotSpot Therapeutics, as part of the From The Trenches feature of LifeSciVC HotSpot’s trip to Barcelona for the recent European Society of Medical Oncology (ESMO) Annual Meeting was no ‘European Vacation,’ but it was certainly

Leave a comment

Reflections On My Experience As A Board Member
September 18, 2024

By Ivana Magovčević-Liebisch, CEO of Vigil Neuroscience, as part of the From The Trenches feature of LifeSciVC In an industry where boom and bust cycles occur regularly and 90 percent of drug candidates fail to reach the market, an outstanding

Leave a comment

Keeping It Simple: What Really Matters For Emerging Enterprises  
September 4, 2024

By Ankit Mahadevia, chairman of Spero Therapeutics, as part of the From The Trenches feature of LifeSciVC A common theme in startup literature is that by cutting a range of unnecessary tasks, a step-change in results will follow.  I’ve found

Leave a comment



Verified by ExactMetrics